{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:38:06Z","timestamp":1787168286726,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bioorg.2025.108737","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:26:53Z","timestamp":1752575213000},"page":"108737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Discovery of imidazo[1,2-b]pyridazine derivatives as potent TRK inhibitors for overcoming multiple resistant mutants"],"prefix":"10.1016","volume":"163","author":[{"given":"Yunsheng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongtian","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108737_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open."},{"key":"10.1016\/j.bioorg.2025.108737_bb0010","doi-asserted-by":"crossref","first-page":"10084","DOI":"10.1021\/acs.jmedchem.6b00850","article-title":"The discovery of a potent, selective, and peripherally restricted Pan-Trk inhibitor (PF-06273340) for the treatment of pain","volume":"59","author":"Skerratt","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108737_bb0015","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1158\/1078-0432.CCR-18-1156","article-title":"Emerging targeted therapy for Tumors with NTRK fusion proteins","volume":"24","author":"Kheder","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108737_bb0020","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1146\/annurev.biochem.72.121801.161629","article-title":"Trk receptors: roles in neuronal signal transduction","volume":"72","author":"Huang","year":"2003","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bioorg.2025.108737_bb0025","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbr.2012.03.010","article-title":"Infusion of BDNF into the nucleus accumbens of aged rats improves cognition and structural synaptic plasticity through PI3K-ILK-Akt signaling","volume":"231","author":"Li","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bioorg.2025.108737_bb0030","doi-asserted-by":"crossref","first-page":"10122","DOI":"10.3390\/ijms140510122","article-title":"TrkB receptor signalling: implications in neurodegenerative, psychiatric and proliferative disorders","volume":"14","author":"Gupta","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108737_bb0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.mce.2009.10.009","article-title":"Rearrangements of NTRK1 gene in papillary thyroid carcinoma","volume":"321","author":"Greco","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.108737_bb0040","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1021\/acs.jmedchem.1c01597","article-title":"Structural Optimization and Structure\u2013Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6 H -pyrimido[5,4- b ][1,4]oxazin-7(8 H)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants","volume":"65","author":"Pan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108737_bb0045","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.molonc.2014.06.001","article-title":"The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition","volume":"8","author":"Ardini","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bioorg.2025.108737_bb0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2015.05.013","article-title":"Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma","volume":"365","author":"Cr\u00e9ancier","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.108737_bb0055","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/nm.3352","article-title":"Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer","volume":"19","author":"Vaishnavi","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2025.108737_bb0060","article-title":"Clinicopathologic features of non-small-cell lung Cancer Harboring an NTRK gene fusion","volume":"2018","author":"Farago","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.bioorg.2025.108737_bb0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1146\/annurev.neuro.26.041002.131421","article-title":"Selectivity in neurotrophin signaling: theme and variations","volume":"26","author":"Segal","year":"2003","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.bioorg.2025.108737_bb0070","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1021\/acs.jmedchem.7b01607","article-title":"Identification of [(18)F]TRACK, a Fluorine-18-Labeled tropomyosin receptor kinase (Trk) inhibitor for PET imaging","volume":"61","author":"Bernard-Gauthier","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108737_bb0075","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108737_bb0080","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1021\/acs.jmedchem.8b01092","article-title":"Insights into current tropomyosin receptor kinase (TRK) inhibitors: development and clinical application","volume":"62","author":"Yan","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108737_bb0085","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.apsb.2020.05.004","article-title":"Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2025.108737_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115618","article-title":"Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: a mini review","volume":"258","author":"El-Nassan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108737_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115953","article-title":"Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance","volume":"264","author":"Qin","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108737_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116640","article-title":"Discovery of novel indazole derivatives as second-generation TRK inhibitors","volume":"276","author":"Qin","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108737_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117608","article-title":"Design, synthesis and evaluate of indazolylaminoquinazoline derivatives as potent tropomyosin receptor kinase (TRK) inhibitors","volume":"99","author":"Xu","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108737_bb0110","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/2159-8290.CD-15-0443","article-title":"An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101","volume":"5","author":"Doebele","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108737_bb0115","doi-asserted-by":"crossref","first-page":"8364","DOI":"10.1021\/acs.jmedchem.9b01259","article-title":"Correction to discovery of Entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ROS oncogene 1 kinase (ROS1), and Pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor","volume":"62","author":"Menichincheri","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108737_bb0120","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108737_bb0125","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1158\/2159-8290.CD-20-0571","article-title":"TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors","volume":"11","author":"Cocco","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108737_bb0130","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid Tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108737_bb0135","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent- front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108737_bb0140","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1021\/jm800343j","article-title":"Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases","volume":"51","author":"Wang","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108737_bb0145","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1158\/1535-7163.MCT-09-0036","article-title":"Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway","volume":"8","author":"Thress","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.108737_bb0150","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1021\/ml300074j","article-title":"Discovery of disubstituted Imidazo[4,5-b]pyridines and purines as potent TrkA inhibitors","volume":"3","author":"Wang","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108737_bb0155","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1021\/acs.jmedchem.8b01630","article-title":"Discovery of potent, selective, and brain-penetrant 1H-Pyrazol-5-yl-1H-pyrrolo[2,3-b]pyridines as anaplastic lymphoma kinase (ALK) inhibitors","volume":"62","author":"Fushimi","year":"2019","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825006170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825006170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:02:42Z","timestamp":1776920562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825006170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":31,"alternative-id":["S0045206825006170"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108737","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of imidazo[1,2-b]pyridazine derivatives as potent TRK inhibitors for overcoming multiple resistant mutants","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108737"}}